Cellular & Molecular Biomarkers in Patients With Lichen Planus

Status Recruiting

Clinical Trial Summary

Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate, associated with epithelial cell death and disruption of the basement membrane zone. In previous work, T cell antigen receptor (TCR) repertoire studies were performed. In all patients tested, whether with erosive or non-erosive LP, unique nucleotide sequences, called clonotypes, have been identified. They appear during the process of TCR gene rearrangement. These clonotypes are specific for human papillomavirus (HPV) in blood and lesions, suggesting antigenic stimulation of these clonotypes by a viral epitope of HPV, which crosses with an epitope on keratinocytes. The diagnosis of LP is made on the basis of clinical and histological criteria, but in some patients and in some anatomical locations, the diagnosis is difficult to make and LP may be confused with other skin conditions.

Clinical Trial Description

Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate, associated with epithelial cell death and disruption of the basement membrane zone. Several triggers have been proposed for LP, including viral antigens. In previous work, T cell antigen receptor (TCR) repertoire studies were performed, i.e. investigating the diversity of TCRs expressed on the surface of an individual's lymphocyte population. In all patients tested, whether with erosive or non-erosive LP, unique nucleotide sequences, called clonotypes, have been identified. They appear during the process of TCR gene rearrangement. These clonotypes are specific for human papillomavirus (HPV) in blood and lesions, suggesting antigenic stimulation of these clonotypes by a viral epitope of HPV, which crosses with an epitope on keratinocytes. The diagnosis of LP is made on the basis of clinical and histological criteria, but in some patients and in some anatomical locations, the diagnosis is difficult to make and LP may be confused with other skin conditions. ;

Study Design

Related Conditions & MeSH terms

Lichen Planus

Clinical Trial Details

NCT number	NCT06451744
Study type	Interventional
Source	Institut Pasteur
Contact	Marie-Lise Gougeon
Phone	1 40 66 97 87
Email	marie-lise.gougeon@pasteur.fr
Status	Recruiting
Phase	N/A
Start date	November 1, 2023
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06021405` - Koebner's Phenomenon in Psoriasis and Lichen Planus	N/A
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Completed	`NCT05787925` - Adjunctive Oral Systemic Vitamin E Therapy on Salivary Nitric Oxide Level in Patients With Erosive Oral Lichen Planus	N/A
Completed	`NCT03630198` - Pain Outcomes Following Intralesional Corticosteroid Injections	Phase 4
Completed	`NCT04952961` - Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study	N/A
Recruiting	`NCT04697563` - Laser Therapy in Women With Lichenoid Disorders	N/A
Completed	`NCT03265093` - Use of Injectable Platelet Rich Fibrin in Lichen Planus	N/A
Completed	`NCT03858634` - A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases	Phase 2
Completed	`NCT02761122` - Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen)	N/A
Active, not recruiting	`NCT00691106` - A Multi-center Study to Evaluate the Safety of Etanercept in the Treatment of Lichen Planus	Phase 2
Terminated	`NCT05761158` - Study of the Characteristics of Pruritus in Patients With Frontal Fibrosing Alopecia or Lichen Planus Pilaris
Recruiting	`NCT02261662` - Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection	N/A
Not yet recruiting	`NCT04892381` - Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
Completed	`NCT05396261` - a Flexible Wound Dressing for the Management of Genital Skin Conditions	N/A
Recruiting	`NCT02532166` - Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus	N/A
Recruiting	`NCT06327620` - Treatment Of Oral Lichen Planus	N/A
Completed	`NCT03796806` - Methods Validation Assessment for Study of Inflammatory Skin Disease
Completed	`NCT02850601` - Dexamethasone Solution for the Treatment of Oral Lichen Planus	Phase 2
Not yet recruiting	`NCT01041625` - Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus	Phase 2
Completed	`NCT00824889` - Exploratory Study of Natural Killer Cells in Human Skin	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cellular and Molecular Biomarkers in Patients With Lichen Planus — HELP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms